AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The Company is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CT:AUP.

$11.38  +1.33 (13.23%)
As of 07/01/2022 15:59:55 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  07/02/2009
Outstanding shares:  141,741,580
Average volume:  3,365,005
Market cap:   $1,424,502,879
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BFWLC09

---

Valuation   (See tab for details)

---

PE ratio:   -9.60
PB ratio:   3.60
PS ratio:   21.48
Return on equity:   -37.54%
Net income %:   -253.66%